Across TCGA pan-cancer cohorts, ADH1B RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated ADH1B data layer compared with 3 for mutation status and 6 for mass-spec protein.
The strongest signal is observed in mesothelioma (MESO), where higher ADH1B RNA is associated with better overall survival. In most high-consensus cancer types, elevated ADH1B expression acts as an unfavorable survival marker, although some lineages such as MESO and LIHC show a favorable association.
MESO, OV, and KIRP are the cancer types where ADH1B RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.